Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is limited data available on EVR in this population.

Methods: We conducted a retrospective chart review of pancreas tx pts converted from MPA to EVR (CONV). Outcomes were compared to pts that received TAC,MPA and steroids (SOC).

Results: Between May 2012-July 2015, 34 pts received a pancreas tx, 21(62%) were CONV(16 SPK, 3 PAK, 2 PTA) an average of 5.9 months after tx. 13 pts remained on SOC (10 SPK, 3 PAK). Baseline characteristics were similar in both groups. Reasons for EVR conversion include: leukopenia, GI SEs, CMV, BK viremia, and disseminated adenovirus. After conversion, there was less leukopenia (57 vs 38%) and GI SEs (57 vs 10%) with EVR. Rates of CMV and BK were similar between pts Pre vs Post-CONV. The pt with adenovirus became non-detectable by 1 mnth post conversion.